


Supplemental Figure 1



Supplemental Figure 1: Study schema for neoadjuvant nivolumab plus ipilimumab in resectable NSCLC (NCT02259621). Patients with surgically resectable AJCC TNM 7th edition stage IB (≥ 4 cm) – IIIA histologically confirmed non-small cell lung cancer (NSCLC) were eligible for inclusion. Nivolumab 3mg/kg IV was given together with ipilimumab 1 mg/kg IV 6 weeks prior to planned resection (D0). Nivolumab 3 mg/kg was given again at approximately 4 and 2 weeks prior to resection. Blood for correlative analyses was drawn pre-treatment, with each dose of neoadjuvant therapy, prior to surgery, and post-operatively. AJCC TNM: American Joint Committee on Cancer Tumor Node Metastases; D0: day 0 (day of surgery); NSCLC: non-small cell lung cancer IV: intravenous.